ReviewBiomedicines2021
From Mitochondria to Atherosclerosis: The Inflammation Path.
Review in Biomedicines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 2 syntheses or guidelines pooled it, 69 citations in OpenAlex.
- Impact of anti-inflammatory diets on cardiovascular disease risk factors: a systematic review and meta-analysis.Frontiers in nutrition · 2025Pooled it
- Bibliometric analysis of research hotspots and emerging trends in mitophagy and atherosclerosis (2004-2024).Frontiers in medicine · 2025Pooled it
- Perirenal Adipose Tissue in Cardiovascular Disease: From Molecular Insights to Therapeutic Perspectives.Biomedicines · 2026Review
- Metainflammation, Mitochondrial Dysfunction, and Organokine Crosstalk: A Central Axis Linking Metabolic Syndrome to Cardiovascular Diseases.International journal of molecular sciences · 2026Review
- Identification of Mitochondrial Signature Biomarkers and Molecular Mechanisms in Atherosclerotic Tissues and Blood: Combined Single-Cell and Bulk RNA Sequencing Analysis.Molecular neurobiology · 2026Article
- Uncovering the molecular mechanism of solasonine in treating interstitial cystitis via network pharmacology and molecular docking.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- HYQTD Drug-containing Serum Alleviates HCurrent pharmaceutical biotechnology · 2026Article
- Spatio-temporal dynamics of autophagy-associated genes in macrophage-driven atherosclerosis: an integrated omics and experimental study.Frontiers in endocrinology · 2026Article
- Herbal targeting of mitochondrial dynamic proteins in low-density lipoprotein driven atherosclerosisFrontiers in cardiovascular medicine · 2026Article
- Ferroptosis in arterial atherosclerosis: mechanistic hypotheses, cell type specific vulnerabilities, translational biomarkers, and therapeutic opportunities.Frontiers in immunology · 2026Review
- Review
- Advanced Proteomics Approaches Hold Potential for the Risk Assessment of Metabolism-Disrupting Chemicals as Omics-Based NAM: A Case Study Using the Phthalate Substitute DINCH.Environmental science & technology · 2025Article
- Role of mitochondria in physiological activities, diseases, and therapy.Molecular biomedicine · 2025Review
- Mechanism of Red Yeast Rice in the Improvement of Atherosclerosis in Apolipoprotein E-deficient Mice Explored Through Metabolomics Combined with Serum Pharmacochemistry and Network Pharmacology.Plant foods for human nutrition (Dordrecht, Netherlands) · 2025Article
- Stromal Cell-Derived Factor-1, P-Selectin, and Advanced Oxidation Protein Products with Mitochondrial Dysfunction Concurrently Impact Cerebral Vessels in Patients with Normoalbuminuric Diabetic Kidney Disease and Type 2 Diabetes Mellitus.International journal of molecular sciences · 2025Article
- Mitochondrial Dysfunction and Atherosclerosis: The Problem and the Search for Its Solution.Biomedicines · 2025Review
- Advanced Research in the Pathophysiology of Venous Thromboembolism-Acute Pulmonary Embolism.Biomedicines · 2025Review
- Dysregulation of Mitochondrial Homeostasis in Cardiovascular Diseases.Pharmaceuticals (Basel, Switzerland) · 2025Review
- miR-369-3p ameliorates diabetes-associated atherosclerosis by regulating macrophage succinate-GPR91 signalling.Cardiovascular research · 2024Article
- The two coin sides of bacterial extracellular membrane nanovesicles: atherosclerosis trigger or remedy.Discover nano · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
Inflammation is a key process in metazoan organisms due to its relevance for innate defense against infections and tissue damage. However, inflammation is also implicated in pathological processes such as atherosclerosis. Atherosclerosis is a chronic inflammatory disease of the arterial wall where unstable atherosclerotic plaque rupture causing platelet aggregation and thrombosis may compromise the arterial lumen, leading to acute or chronic ischemic syndromes. In this review, we will focus on the role of mitochondria in atherosclerosis while keeping inflammation as a link. Mitochondria are the main source of cellular energy. Under stress, mitochondria are also capable of controlling inflammation through the production of reactive oxygen species (ROS) and the release of mitochondrial components, such as mitochondrial DNA (mtDNA), into the cytoplasm or into the extracellular matrix, where they act as danger signals when recognized by innate immune receptors. Primary or secondary mitochondrial dysfunctions are associated with the initiation and progression of atherosclerosis by elevating the production of ROS, altering mitochondrial dynamics and energy supply, as well as promoting inflammation. Knowing and understanding the pathways behind mitochondrial-based inflammation in atheroma progression is essential to discovering alternative or complementary treatments.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.